Pathways for the emergence of multi-dideoxynucleoside-resistant HIV-1 variants

@article{Matsumi2003PathwaysFT,
  title={Pathways for the emergence of multi-dideoxynucleoside-resistant HIV-1 variants},
  author={Shintaro Matsumi and Pope Kosalaraksa and Hsinyi Tsang and Mark F. Kavlick and Shigeyoshi Harada and Hiroaki Mitsuya},
  journal={AIDS},
  year={2003},
  volume={17},
  pages={1127-1137}
}
Objective: To investigate the mechanism by which the Q151M mutation in reverse transcriptase (RT) that confers multi-dideoxynucleoside resistance on HIV-1 and that requires a two base change (CAG←ATG) develops, and to understand the reason for the relatively lengthy period of time required for its emergence under therapy with multiple nucleoside RT inhibitors (NRTI). Design and methods: Propagation assays and competitive HIV-1 replication assays were used to evaluate the fitness of various… Expand
Mechanism of Resistance to GS-9148 Conferred by the Q151L Mutation in HIV-1 Reverse Transcriptase
TLDR
It is concluded that Q151L severely compromises binding of GS-9148–diphosphate to RT, and it is demonstrated that another NtRTI, tenofovir, is incorporated with selectivity similar to that seen with wild-type RT. Expand
Mutation V111I in HIV-2 Reverse Transcriptase Increases the Fitness of the Nucleoside Analogue-Resistant K65R and Q151M Viruses
TLDR
Analysis of the polymerase, connection, and RNase H domains of RT in HIV-2 patients failing NRTI-containing therapies shows that V111I does not strongly affect drug susceptibility but increases the replication capacity of the K65R and Q151M viruses. Expand
Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs).
TLDR
The development of NRTIs that would not allow the ATP-mediated excision to take place should prove beneficial for future treatments, even though high-level resistance to multiple N RTIs can ultimately develop in the absence of any significant primer unblocking. Expand
The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains
TLDR
A complex interplay between drug susceptibility and replicative fitness in the acquisition Q151M MDR with serious implications for second-line regimen options is demonstrated. Expand
Molecular mechanisms of HIV-1 resistance to nucleoside and nucleotide reverse transcriptase inhibitors
TLDR
The thymidine analog mutations – such as M41L, D67N, K70R, L210W, T215F/Y and K219Q – augment the ability of HIV-1 RT to excise a chain-terminating NRTI monophosphate from a prematurely terminated DNA chain. Expand
Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway
TLDR
This work demonstrates that mutant M41L/D67N/K70R/S215Y HIV-2 RT lacks ATP-dependent excision activity, and recombinant virus containing this RT remains susceptible to AZT inhibition, and highlights critical HIV- 2 RT residues impeding the development of excision-mediated NRTI resistance. Expand
Mutations in HIV-1 Reverse Transcriptase Affect the Errors Made in a Single Cycle of Viral Replication
TLDR
Data show that changes either in HIV-1 RT or in the sequence of the nucleic acid template can affect the spectrum of mutations made during viral replication, which could affect the generation of drug-resistant mutants and immunological-escape mutants in patients. Expand
Mutation V 111 I in HIV-2 Reverse Transcriptase Increases the Fitness of the Nucleoside Analogue-Resistant K 65 R and Q 151 M Viruses
Infection with HIV-2 can ultimately lead to AIDS, although disease progression is much slower than with HIV-1. HIV-2 patients are mostly treated with a combination of nucleoside reverse transcriptaseExpand
K70Q Adds High-Level Tenofovir Resistance to “Q151M Complex” HIV Reverse Transcriptase through the Enhanced Discrimination Mechanism
TLDR
The novel pattern of TFV-resistance may help adjust therapeutic strategies for NRTI-experienced patients with multi-drug resistant (MDR) mutations. Expand
Evolution of a novel 5-amino-acid insertion in the β3-β4 loop of HIV-1 reverse transcriptase
TLDR
The novel RT insertion variant conferring low levels of resistance was able to evolve towards a high-level resistant replication-competent variant, and mathematical analyses of longitudinal samples indicated a 2% in vivo fitness advantage for the insertion variant compared to the initial viral population. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 37 REFERENCES
Comparative Fitness of Multi-Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) in an In Vitro Competitive HIV-1 Replication Assay
TLDR
It is demonstrated that several MDR HIV-1 variants are more fit than HIV- 1wt in the absence of drugs and that resistance-associated mutations and drug pressure are critical variates for HIV-2 fitness. Expand
Evidence of a Role for the Q151L Mutation and the Viral Background in Development of Multiple Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1
TLDR
The demonstrated ability of HIV-1151L/68G to replicate and the associated MDNR suggest that 151L is a potential intermediate of Q151M, which may explain the low frequency of the Q 151M-mediated pathway of resistance. Expand
Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
TLDR
The reproducible nature of these mutations should make it possible to develop rapid assays to predict zidovudine resistance by performing polymerase chain reaction amplification of nucleic acid from peripheral blood lymphocytes, thereby circumventing current lengthy HIV isolation and sensitivity testing. Expand
Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype
TLDR
Changes in the non-nucleoside binding pocket must affect the conformation of residues at the dNTP binding site, and can result in a partial phenotypic reversal of the multi-n nucleoside resistance phenotype. Expand
Second-Site Reversion of a Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutant That Restores Enzyme Function and Replication Capacity
TLDR
Examination of available crystal structures of HIV-1 RT suggests a possible mechanism for restoration of enzyme activity by the second-site revertant, and demonstrates that M230I mitigates the polymerase activity defect of the Y115W mutant, by increasing the dNTP binding affinity of the enzyme. Expand
Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.
TLDR
Analysis of HIV-1 strains isolated at various times during therapy showed that the Q151M mutation developed first in vivo, at the time when the viremia level suddenly increased, followed by the F116Y and F77L mutations, and all five mutations ultimately developed, and the viresmia level rose even further. Expand
Enzymatic Characterization of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistant to Multiple 2′,3′-Dideoxynucleoside 5′-Triphosphates (*)
TLDR
The alteration of RT's substrate recognition, caused by these mutations, accounts for the observed multi-ddN resistance of HIV-1. Expand
Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy.
TLDR
A set of five reverse transcriptase mutations, which include Q151M, is known to confer multi-dideoxynucleoside resistance (MDR) in human immunodeficiency virus type 1 (HIV-1), were found in 6 patients, most of whom were receiving long-term combination therapy. Expand
Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance.
TLDR
The virologic features of these infectious mutants suggest that HIV-1 develops drug resistance through one or more mutations, which, however, sacrifice replicative capability; then it finally acquires optimal replication competence by additional mutations when the multi-dideoxynucleoside-resistant mutant emerges. Expand
Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2',3'-dideoxynucleotide analogs using the single-nucleotide incorporation assay.
TLDR
The observed cross-resistance of HIV-1 RT to various ddNTPs should reflect the alteration of RT's substrate recognition and should provide insights into the molecular mechanism of RT discrimination of ddN TPs from natural substrates. Expand
...
1
2
3
4
...